Tonix Pharmaceuticals (NASDAQ: TNXP) is working to improve organ transplant success rates with TNX-1500, a third-generation CD40L blocker designed to ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D ...

Investors interested in arranging a meeting with the Company's management virtually during the conference should contact the ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink ...

细胞毒性T细胞抗肿瘤免疫应答主要取决于cDC1s的交叉呈递抗原的能力。一旦激活并通过CD40-CD40L相互作用感知到辅助T细胞，cDC1就会提供关键的共刺激配体和细胞因子，以建立和维持CD8+T细胞免疫反应，这种同源T细胞活化的调节过程称为交叉启动。 在癌症小鼠模型 ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China Clinical Cancer Institute of Nanjing University, ...

The drug candidate is a humanized anti-CD40L monoclonal antibody. It acts by targeting CD40 ligand (CD40L) and is administered through intravenous and subcutaneous routes. The drug candidate was also ...

Serum specimens of AIDS-NHL cases were collected at a mean time of 1.25 years (range of 2 to 36 months) prior to an AIDS-NHL diagnosis. The expression of PD-L1 and other molecules on EVs (CD40, CD40L, ...